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DIETARY IMPACTS ON INTESTINAL MICROBIAL COMMUNITY AND 
CARDIOVASCULAR DISEASES 
 
NAVTEJ ATWAL 
 
ABSTRACT 
Objective. Chapter 1: Investigate the impact that trimethylamine N-oxide (TMAO), 
dietary contribution of short chain fatty acids (SCFAs), and role of bile acids has on 
cardiovascular health and disease. Chapter 2: Evaluate the association between intakes of 
dietary protein from both animal and plant sources on lipid profile changes. 
Methods. Chapter 1: Literature review using PubMed and EMBASE to search for 
published studies for dietary intake or supplementation impact on TMAO or its 
precursors and their role in the development or prevention of cardiovascular diseases. 
Chapter 2: Framingham Offspring Study, prospective cohort study using statistical 
methods to investigate the changes in lipid profiles with dietary animal and plant protein.   
Published Studies/Results. Chapter 1: The increased risk of cardiovascular diseases 
(CVD) correlates with increasing levels of circulating levels of TMAO. The risk of CVD 
in animal and human studies have shown to be distinct in groups with and without CVD, 
leading to either beneficial or adverse effects from the consumption of dietary 
phosphatidylcholine, choline, betaine, carnitine, or intact TMAO. A Western dietary 
approach has been linked with the development of dyslipidemia whereas, adherence to a 
Mediterranean diet reduces the risk of major CVD events. The dietary precursors 
 vii 
involved in TMA production by the gut microbiota then respectively to TMAO through 
hepatic enzyme FMO3 provide both beneficial and detrimental effects. Mechanisms of 
action for TMAO on CVD risk involves changes associated with cholesterol and sterol 
metabolism leading to foam cell formation, and enhancement of scavenger receptors, 
CD36 and scavenger receptor-A, on macrophages affects the rate of cholesterol influx 
and efflux. Choline derived in a dose-dependent manner from eggs improves 
cardiometabolic biomarkers with no changes in fasting TMAO. Further, choline from 
eggs also increases the lipoprotein particle size for both HDL-cholesterol and LDL-
cholesterol increasing the rate of reverse cholesterol transport (RCT). Betaine 
concentrations in humans are associated with health outcomes based on an individual’s 
overall systemic health at baseline. Supplementation with L-carnitine produced favorable 
effects in lean subjects compared to obese subjects, improved cardiometabolic status in 
patients with myocardial infarction, and improved lipid profiles among individuals with 
prevalent coronary heart disease (CAD).  Fish consumption increases concentrations of 
TMAO due to its high levels of intact TMAO though, protective effects for CVD are 
obtained from fatty fish providing omega-3-fatty acids impacting positive changes in the 
lipid profiles. Antibiotic therapy suppresses the gut microbiota and eliminates the 
production of TMA from the dietary precursors that are required.  Chapter 2: Men and 
women both showed a decreasing trend for LDL-cholesterol as the tertiles increased for 
animal protein intake. Plant protein intake showed a similar decreasing trend for LDL-
cholesterol with increasing protein tertiles; however, men had inconsistency among the 
trend whereas women had a consistent decreasing trend. HDL-cholesterol content 
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increases in males and females with both increasing tertiles for animal and plant protein, 
though plant protein presented much stronger effects when compared to animal protein. 
Log-transformed triglycerides were inversely associated with increasing animal protein 
intake, men revealing greater effects than females. Plant protein intake showed a stronger 
effect than animal protein intake in an increasing trend in the log of triglycerides over the 
6 exams. Overall, total cholesterol content varied at each examination period, animal 
protein intake tertiles displayed decreased level of total cholesterol, there was a greater 
effect in men than women. Higher intake of plant protein had a similar trend to animal 
protein intake showing a decrease in the total cholesterol concentration. Women had a 
much greater effect in reducing total cholesterol with plant protein when compared to 
men. 
Conclusion. Chapter 1: Multiple human and animal trials addressed in the association 
between diet, dietary precursors, gut microbiota composition, and their derived 
metabolite TMAO on the presence or absence of CVD display contradictory results and 
identifies areas needing further study. Chapter 2: Regardless of the source of protein, the 
lipid profiles improved with the intake of either animal or plant protein as the protein 
intake was increased over the tertiles in each exam. The overall trend with increasing 
animal or plant protein intake led to decrease in LDL-cholesterol, log transformed 
triglycerides, and total cholesterol whereas, the HDL-cholesterol concentrations were 
increased. Men favored animal protein intake to show greater reductions in LDL-
cholesterol and total cholesterol, whereas women favored plant protein. The increase in 
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HDL-cholesterol concentration was stronger with the intake of plant protein in men and 
women. The changes in log transformed triglycerides were similar in men and women.  
  
 x 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS .................................................................................................... x 
LIST OF TABLES ............................................................................................................ xii 
LIST OF FIGURES ......................................................................................................... xiii 
LIST OF ABBREVIATIONS .......................................................................................... xvi 
CHAPTER 1 – Dietary Impacts On Intestinal Microbial Community and Cardiovascular 
Diseases ............................................................................................................................... 1 
INTRODUCTION .............................................................................................................. 1 
METHODS and PUBLISHED STUDIES .......................................................................... 3 
Trimethylamine N-Oxide in CVD ........................................................................... 3 
Phosphatidylchiline, Choline, L-carnitine, Betaine and TMA/TMAO Pathway  
..................................................................................................................................... 6 
Short-chain Fatty Acids ............................................................................................ 8 
 xi 
Diet, Genes and TMAO .......................................................................................... 10 
Fish Consumption ................................................................................................... 12 
Phosphatidylcholine/Choline ................................................................................. 12 
L-Carnitine .............................................................................................................. 14 
Diet Patterns ............................................................................................................ 15 
Microbes ................................................................................................................... 17 
DISCUSSION ................................................................................................................... 21 
CHAPTER 2 – Framingham Offspring Study – Animal and Plant Protein Intake and 
Dietary Lipids ................................................................................................................... 26 
INTRODUCTION ............................................................................................................ 26 
METHODS ....................................................................................................................... 29 
Study Sample ........................................................................................................... 29 
Lipid and Lipoprotein Particle Measurements .................................................... 30 
Potential Confounding Variables .......................................................................... 31 
Statistical Methods .................................................................................................. 32 
RESULTS ......................................................................................................................... 34 
DISCUSSION ................................................................................................................... 55 
LIST OF JOURNAL ABBREVIATIONS ....................................................................... 59 
REFERENCES ................................................................................................................. 64 
CURRICULUM VITAE ................................................................................................... 80 
 xii 
 
LIST OF TABLES 
 
 
Table Title Page 
1 Characteristics of the Framingham Offspring Study 
subjects according to tertiles of intake of animal protein in 
the diet 
34 
2 Characteristics of the Framingham Offspring Study 
subjects according to tertiles of intake of plant protein in 
the diet 
36 
  
 xiii 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 LDL Cholesterol according to Weight-adjusted Animal 
Protein at Exams 3-8 (All Subjects) 
38 
2 LDL Cholesterol according to Weight-adjusted Animal 
Protein at Exams 3-8 (Men Only) 
39 
3 LDL Cholesterol according to Weight-adjusted Animal 
Protein at Exams 3-8 (Women Only) 
39 
4 LDL Cholesterol according to Weight-adjusted Plant 
Protein at Exams 3-8 (All Subjects) 
40 
5 LDL Cholesterol according to Weight-adjusted Plant 
Protein at Exams 3-8 (Men Only) 
41 
6 LDL Cholesterol according to Weight-adjusted Plant 
Protein at Exams 3-8 (Women Only) 
42 
7 HDL Cholesterol according to Weight-adjusted Animal 
Protein Intakes at Exams 3-8 (All Subjects 
42 
8 HDL Cholesterol according to Weight-adjusted Animal 
Protein Intakes at Exams 3-8 (Men Only) 
43 
9 HDL Cholesterol according to Weight-adjusted Animal 44 
 xiv 
Protein Intakes at Exams 3-8 (Women Only) 
10 HDL Cholesterol according to Weight-adjusted Plant 
Protein Intakes at Exams 3-8 (All Subjects) 
44 
11 HDL Cholesterol according to Weight-adjusted Plant 
Protein Intakes at Exams 3-8 (Men Only) 
46 
12 HDL Cholesterol according to Weight-adjusted Plant 
Protein Intakes at Exams 3-8 (Women Only) 
46 
13 Log of Triglycerides according to Weight-adjusted Animal 
Protein Intake at Exams 3-8 (All Subjects) 
47 
14 Log of Triglycerides according to Weight-adjusted Animal 
Protein Intake at Exams 3-8 (Men Only) 
47 
15 Log of Triglycerides according to Weight-adjusted Animal 
Protein Intake at Exams 3-8 (Women Only) 
48 
16 Log of Triglycerides according to Weight-adjusted Plant 
Protein Intake at Exams 3-8 (All Subjects) 
49 
17 Log of Triglycerides according to Weight-adjusted Plant 
Protein Intake at Exams 3-8 (Men Only) 
49 
18 Log of Triglycerides according to Weight-adjusted Plant 
Protein Intake at Exams 3-8 (Women Only) 
50 
19 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Animal Protein Intake (All Subjects) 
50 
 xv 
20 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Animal Protein Intake (Men Only) 
52 
21 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Animal Protein Intake (Women Only) 
52 
22 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Plant Protein Intake (All Subjects) 
53 
23 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Plant Protein Intake (Men Only) 
53 
24 Total Cholesterol, Exams 3-8, according to Weight-
adjusted Plant Protein Intake (Women Only) 
54 
   
  
 xvi 
LIST OF ABBREVIATIONS 
 
ANCOVA ......................................................................................... Analysis of covariance 
Apo-A1 ................................................................................................... Apolipoprotein A1 
Apo E-/- ..................................................................................... Atherosclerosis prone mice 
ATP .................................................................................................. Adenosine triphosphate 
BHMT .................................................................. Betaine homocysteine methyl transferase 
CAD ................................................................................................. Coronary artery disease 
CETP .................................................................................. Cholesterolester transfer protein 
CoA ................................................................................................................... Coenzyme A 
CVD ................................................................................................ Cardiovascular diseases 
DASH ................................................................. Dietary Approaches to Stop Hypertension 
DMB ............................................................................................... 3.3-Dimethyl-1-butanol 
DMG ........................................................................................................... Dimethylglycine 
FMO3 .......................................................................... Flavin-containing monooxygenase 3 
FXR ...................................................................................................... Farnesoid X receptor 
HDL ............................................................................................... High density lipoprotein 
HDL-P .............................................................................. High density lipoprotein particles 
HMG CoA  ..................................................................... 3-hydroxy-3-methyl-glutaryl-CoA 
LC ........................................................................................................................ L-carnitine 
LDL ................................................................................................. Low density lipoprotein 
MUFA ...................................................................................... Monounsaturated fatty acids 
NMR ........................................................................................ Nuclear magnetic resonance 
 xvii 
PEMT ........................................................ phosphatidylethanolamine-N-methyltransferase 
PUFA ......................................................................................... Polyunsaturated fatty acids 
RCT ......................................................................................... Reverse cholesterol transport 
RS .............................................................................................................. Resistant starches 
SCFA ................................................................................................. Short chain fatty acids 
SD ........................................................................................................... Standard deviation 
TAC........................................................................................ Transverse aortic constriction 
TG .................................................................................................................... Triglycerides 
TMA ............................................................................................................. Trimethylamine 
TMAO ............................................................................................ Trimethylamine N-oxide 
VLDL ...................................................................................... Very-low density lipoprotein 
VLDL-P .................................................................... Very-low density lipoprotein particles 
WD ........................................................................................... High-fat and high sugar diet
 1 
CHAPTER 1- Dietary Impacts on Intestinal Microbial Community and 
Cardiovascular Diseases 
INTRODUCTION 
 
Cardiovascular diseases (CVD) are leading causes of morbidity and mortality 
worldwide1. Varying risk factors lead to the pathogenesis of atherosclerosis,2 including 
dyslipidemia, hypertension, smoking, and diabetes3. Diet also plays a critical role in the 
prevention of CVD and its associated risk factors.  
Dyslipidemia, which involves elevated levels of total cholesterol, low-density 
lipoproteins (LDL) and/or triglycerides, and low levels of high density lipoprotein (HDL) 
cholesterol is largely a result of an atherogenic lifestyle which, in terms of dietary habits. 
Healthy dietary patterns such as a Mediterranean-style diet rich in monounsaturated fatty 
acids (MUFAs), polyunsaturated fatty acids (PUFAs) and complex carbohydrates, or a 
diet similar to that derived from the “Dietary Approaches to Stop Hypertension” (DASH) 
clinical trials, have been strongly correlated with reduced incidence of CVD4-6. While 
medical therapies such as the use of statins to reduce cholesterol synthesis by inhibiting 
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase)3,7,8, and anti-
hypertensive treatments are critically important methods for treating patients with 
prevalent CVD, 3,9,10 the ideal approach would be to prevent CVD from occurring and 
progressing in the first place3,11.  
Our understanding of the pathogenesis of CVD has been dramatically shifting in 
recent years. In particular, scientists are increasingly recognizing the important role of gut 
flora in the development of atherosclerosis and as a result, we need to rethink our 
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understanding of the role of diet and nutrition-related exposures. Two key nutrients – 
choline and L-carnitine—play particularly important roles.  
In recent years, a growing number of studies have considered the meta-organismal 
actions and interactions of gut microbiota and their contribution to the risk of CVD. The 
human microbiota consists of 1014 bacterial, fungal, archaeal, and viral cells per person 
with a majority of the microbiota constituted in the human caecum and colon12,13. In 
healthy individuals, the gut microbiome is comprised of >90% of anaerobic Bacteroidetes 
and Firmicutes, although the ratio of these phyla varies among individuals as a result of 
altered host genomes and environmental factors including antibiotic use, lifestyle, 
hygiene, and diet13-16.The gut microbiota contributes to a wide range of functions 
including nutrient metabolism.  
The mechanisms by which the gut microbiota lead to CVD include the 
trimethylamine/ trimethylamine N-oxide (TMA/TMAO) pathways, secondary bile acid 
pathways, and those involving short-chain fatty acids (SCFAs)3,13,17-23. The goal of this 
chapter is first to investigate the impact of trimethylamine N-oxide (TMAO) on CVD 
risk. The second objective is to examine the dietary contribution of SCFAs to 
cardiovascular health and disease, and lastly consider the role of bile acids in the above 
mechanisms. 
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METHODS AND PUBLISHED STUDIES 
 
PubMed and EMBASE databases were searched without language restrictions for 
human and animal studies. The types of articles included are clinical trials, randomized 
controlled trials, literature reviews, meta-analysis, and systematic review. Primary search 
terms included TMAO, gut microbiota, diet, short chain fatty acids (SCFA), 
phosphatidylcholine, choline, L-carnitine, betaine, and CVD. Articles were selected 
based on the relevance of the title and abstract for dietary intake or supplementation of 
TMAO or its precursors in the development or prevention of CVD.  
 
Trimethylamine N-oxide in CVD 
TMAO is a gut microbe-derived metabolite that in high concentrations is 
associated with an increased risk of CVD and cardiovascular death23,24. Patients already 
diagnosed with CVD have been shown to have increased TMAO levels, a finding that has 
been associated with premature death, incident myocardial infarction and stroke 
compared with those who have relatively low TMAO concentrations25. In a study of 
subjects with prevalent coronary artery disease (CAD), circulating TMAO concentrations 
were linked with the development of coronary plaque26. Still another follow-up study of 
subjects with stable heart failure, found that higher circulating levels of TMAO predicted 
higher long-term mortality risk independent of conventional risk factors27,28. 
TMAO is present in large quantities in marine animals and is also synthesized by 
gut microbes from the precursors, phosphatidylcholine, choline, betaine, and L-
carnitine24. TMAO is synthesized in the liver from an intermediate compound, TMA, 
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which is derived from gut microbiota utilizing the above dietary precursors18,24,29. Human 
and animal studies have demonstrated that microbes in the gut provide a host metabolic 
pathway for the production of TMA2 although the specific microbes involved are less 
clear. The bioavailability of TMA is dependent on the concentration and digestion of the 
above-mentioned dietary precursors found in food. TMA production has also been shown 
to be suppressed during antibiotic treatment due to the absence of the necessary gut 
microbes29.  
TMAO has been found to be pro-atherogenic, leading to an increased risk for 
CVD outcomes in some recent studies17,24,30. It is synthesized by flavin monooxygenase 3 
(FMO3), a host hepatic enzyme that rapidly oxidizes TMA18,31. It is hypothesized that 
TMAO suppresses reverse cholesterol transport (RCT) and bile acid synthesis, thereby 
promoting plaque formation in the arteries. RCT is an essential process required for the 
removal of excess cholesterol from the arterial walls2,3,32,33. This excess cholesterol is 
then excreted from the liver either directly or following conversion to bile salts.  
Bile acids are part of a major pathway involved in removal of excess 
cholesterol22.  Reduction in bile acid synthesis has been seen in mice supplemented with 
TMAO, thereby leading to reduced mRNA expression of the enzymes Cyp7a1 and 
Cyp27a1, and altered cholesterol metabolism associated with this reduction in bile acid 
availability3,30. Blocking the bile acid pathway may have pro-atherosclerotic 
consequences. Bile consists of a significant portion of phosphatidylcholine, suggesting 
that since bile is consistently synthesized, the content of phosphatidylcholine would 
appear at elevated levels, an increased concentration of TMAO to occur in circulation. 
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However, this does not take place and may be due to the biliary phosphatidylcholine 
absorbption in the ileum rather than reaching the cecum/colon where the gut microbiota 
will contribute in the TMA production3,22.  
Given the link between high concentrations of TMAO and major cardiovascular 
events, it is important to understand both the beneficial and detrimental effects of 
consuming diets rich in phosphatidylcholine, choline, betaine, L-carnitine, and TMAO 
itself. The ample amount of TMAO present in fish, for example, would suggest that fish 
would be associated with an increased risk for CVD2,34-37. However, this is not the case. 
Dietary consumption of fish such as cod increases plasma TMAO levels remarkably in 
human studies 3,38 but numerous studies have shown either a protective effect of diets rich 
in fish intake on CVD risk39,40 or no association at all41-43. Similarly, egg consumption 
has been shown to be either beneficial or at least no adverse effect on CVD risk38,44-49.  
Many epidemiologic studies have found contrasting effects for red meat and fish 
in terms of CVD risk18,50. However, red meat intake includes both processed meats and 
lean unprocessed meats; an increasing number of studies have found no adverse effect of 
unprocessed red meats on risk of CVD51,52 Determining the effects of dietary intake 
patterns on health risk is difficult and must consider the intakes of both nutrients and their 
food sources. Too little and too much of a given nutrient typically poses harmful 
consequences, with ideal intakes being somewhere in the middle. L-Carnitine is an 
essential nutrient (to be discussed later) that is required to move long chain fatty acids 
into the cell mitochondria for energy production. Recently, L-carnitine consumption has 
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come under increasing scrutiny as a gut microbe-derived metabolite associated with 
increased risk for CVD.  
 
Phosphatidylcholine, Choline, L-carnitine, Betaine and TMA/TMAO Pathways 
Phosphatidylcholines are a class of naturally occurring phospholipids derived 
directly from dietary sources such as soybeans, eggs, red meats, and peanutes3,23,3,29.   
Phosphatidylcholine is a major component in cell membranes and aids in biological 
membrane stability, cell signaling, and lipid metabolism and transport. 
Phosphatidylcholine serves as the main source of choline in the body. Upon consumption, 
phosphatidylcholine is cleaved to release choline, which serves as a precursor for the 
neurotransmitter acetylcholine3,23 as well as methyl group metabolism53,54..Choline is 
metabolized by gut microbiota, thereby producing TMA which is transported to the liver 
and synthesized into TMAO via Flavin-containing monooxygenase 3 (FMO3). FMO3 
catalyzes epinephrine, nor epinephrine and many xenobiotics and drugs as well as 
Trimethylamine (TMA). Additionally, FMO3 is involved in metabolism of many 
biological processes such as oxidative deamination. In a cross-over trial, consuming more 
than 2 eggs increased the TMAO levels within 4-6 hours55. However, the pre- and post-
trial changes in oxidized LDL and serum CRP did not indicate any deleterious risk of 
CVD55. Free choline is absorbed in the small intestines while phosphatidylcholine 
absorbed intact via the lymphatic system or is hydrolyzed by pancreatic lipases and 
absorbed as glycerophosphocholine55. Thus, the veracity of the report by Tang et al. that 
TMAO level may increase the risk of CVD is somewhat questionable. 
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L-Carnitine (LC) is found in animal source foods, especially meat, poultry, and 
fish, and to a lesser degree, dairy products3,18,29. It can also be synthesized from the amino 
acids lysine and methionine 3,29, especially among those with low LC-containing diets 
such as vegetarians, including lacto-ovo-vegetarians. It has been shown despite dietary 
differences, carnitine plasma concentrations and urinary carnitine excretion across groups 
of omnivores and different types of vegetarians are relatively similar. The minor 
differences across groups suggests that the carnitine biosynthesis and renal conservation 
mechanisms to be sufficient to prevent carnitine deficiency and maintain an adequate 
carnitine concentration56.  
LC serves as a substrate for TMAO synthesis by gut microbiota. LC plays a role 
in esterification of fatty acyl-CoA esters into fatty acyl carnitine, which crosses the 
mitochondrial membrane where fatty acid beta-oxidation occurs, resulting in the 
generation of adenosine triphosphate (ATP) 3,57. Acyl-CoA is a temporary compound 
formed when coenzyme A (CoA) attaches to the end of a long-chain fatty acid. Recently, 
studies have suggested LC may also have antioxidant and anti-inflammatory functions57. 
LC has been shown to suppress the formation of reactive oxygen species through the 
inhibition of nuclear factor-kappa β (NF-kβ) pathway57, a family of transcription factors 
shown to have a protective role on ischemic myocardial injuring during apoptotic cell 
death58,59. Lastly, carnitine acetyltransferase enzyme contributes to carbohydrate 
metabolism by transporting acetylcarnitine out the mitochondrial matrix and into the 
cytosol3. Hence, the acetyl-CoA inhibition of pyruvate dehydrogenase attenuates glucose 
oxidation3. In recent randomized trial, LC supplementation at a dose of 1000 mg/d 
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showed significantly increased in HDL-C and Apo-A1 levels and a slight decrease in TG 
levels but no other changes in other lipids in CAD patients57. Again, these changes are 
not in the direction of increased CVD risks.  
Betaine is a third substrate used in the synthesis of TMAO. TMA is derived from 
betaine via gut microbiota which then will lead to the hepatic production of TMAO 
catalyzed by FMO3. A vegetarian diet is likely to contain higher concentrations of 
betaine derived from sources such as whole grains, beetroot, and spinach29,60. While 
vegetarians are known to have lower risks of CVD and increased levels of betaine18,60, it 
is uncertain whether betaine plays a direct role in the reduction of CVD risk. Betaine may 
also be synthesized from choline in the liver and kidneys through a two-step irreversible 
oxidation process involving choline dehydrogenase 29,61. Betaine acts as a methyl donor 
in homocysteine methylation to form methionine which is mediated by betaine 
homocysteine methyl transferase (BHMT) 29,60. Numerous studies have linked increased 
cardiovascular risk with increased homocysteine levels62. However, betaine helps to 
convert homocysteine to methionine and the CVD risk associated with Betaine 
metabolism is again questionable63. 
 
Short-chain Fatty Acids 
Resistant starches (RS) are indigestible carbohydrates composed largely of 
polysaccharides and involved in the formation of short-chain fatty acids (SCFA) in the 
caecum and colon12,64. SCFA, are primarily acetate, butyrate, and propionate, are 
produced by the gut microbiota during colonic fermentation of these non-digestible 
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carbohydrates 65. Alternatively, protein and amino acid decomposition may also produce 
SCFA, and the gut microbiota composition is responsible for the type and quantity of 
SCFA produced 64.  
Butyrate, in particular, is a key energy source for colonocytes and contributes to 
gut barrier functions 64,66,67. Butyrate is produced by gut microbiota via the acetate CoA-
transferase pathway68. Colonial gut microbiota producing butyrate predominantly belong 
to the Firmicutes phylum characterized by gram positive, anaerobic, oxygen sensitive, 
saccharolytic bacteria66. The most dominant species producing butyrate found in the gut 
belonging to Faecalibacterium prausnitzii and Eubacterium rectale, and others include 
Roseburia spp. and Eubacterium spp.66,69. The abundance of F. prausnitzii has been 
shown to increase anti-inflammatory peptides. TNF-α-induced MCP-1 expression was 
attenuated by SCFAs, especially propionate in human renal cortical epithelial cells as a 
main component of kidney tissue. This suggests that SCFA could be a new therapeutic 
tool for preventing progression of renal inflammation and fibrosis65. Some studies have 
shown that patients with inflammatory conditions carry a relatively low abundance of 
butyrate-producing bacteria in the gut66. 
Finally, it is important to consider that SCFA and the gut microbiota have been 
linked with both pathological conditions as well as health benefits64. In vitro, ex vivo, and 
animal studies have found that SCFAs have anti-inflammatory and anti-carcinogenic 
effects67. Prebiotic and probiotic approaches are being researched to deliver to stimulate 
the bacterial population in the gut aiding in health benefits. 
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Diet, Genes and TMAO 
In a multiethnic Canadian study by Mente et al., levels of TMAO were positively 
associated with prevalent CVD when adjusted for age, sex, BMI, smoking, and energy 
intake. Further, adjustment for diabetes status, meat, fish, and cholesterol intake 
strengthened the adverse effect of TMAO on CVD70. In a study of CD1 mice, with more 
genetic diversity, consuming a healthy (versus Western) diet, mice on the Western diet 
had higher plasma triglycerides and cholesterol levels and subsequently, increased 
plasma TMAO levels32. The increased plasma TMAO levels in Western diet fed mice 
resulted in a surge of inflammation and interstitial fibrosis, leading to cardiac 
dysfunction32. Dimethyl-1-butanol, an inhibitor of TMAO had no effects on body weight 
and dyslipidemia, but significantly reduced plasma TMAO levels and prevented cardiac 
dysfunction in mice fed a high fat and high sugar diet (WD). In addition, mice fed a WD 
had elevated expression of pro-inflammatory cytokines tumor necrosis factor-α and 
interleukin IL-1β, decreased expression of anti-inflammatory cytokine IL-10, and 
increased interstitial fibrosis in the hearts. DMB treatment also reduced plasma TMAO 
levels in mice fed a ND but did not alter other parameters. These results suggest that 
consumption of a WD increases circulating TMAO levels, which lead to cardiac 
inflammation and fibrosis. However, whether WD or the substrate for TMAO is the cause 
for cardiac dysfunction is not clear32.  In a short-term study of a high-fat diet meal 
challenge involving human participants, Boutagy et al. found elevated levels TMAO 
postprandially but no difference in fasting plasma TMAO levels2.  
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Bennet et al. revealed genetic regulation in the oxidation of TMA to TMAO in 
mice through the hepatic enzyme FMO3. Up regulation FMO3 gene expression in mice 
led to a high concentration of plasma TMAO when the FMO3 gene is overexpressed 
whereas lower plasma TMAO levels are seen when FMO3 gene is silenced71. 
Interestingly, Bennet et al. found that expression of FMO3 in mice regulated by farnesoid 
X receptor (FXR), a nuclear receptor activated by dietary bile acid71. Compellingly, 
Sayin et al. discovered bile acid activating FXR is owing to beta and alpha-muricholic 
acid (main forms of bile acid detected in mice) produced in the gut of mice through local 
microbiota, leading to a decrease in liver bile acid72. Another study involving mice may 
explain the effect of elevated plasma TMAO concentrations on suppression of the RCT 
pathway thus decreasing the bile acid pool18. Atherosclerosis prone mice models (Apo E-
/-), boosted the formation of foam cells and minimized RCT transport through 
suppression of the major bile acid enzyme Cyp7a1 activity when supplemented with 
TMAO17,18,30. Collins et el. noticed a protective effect on TMAO administration in Apo 
E-/- mice infected with adeno-associated viral vector containing human cholesterolester 
transfer protein (CETP)33. The two distinct paths of bile acid and TMAO synthesis 
uncovers a metabolic TMAO cycle was regulated through both gut microbiota and bile 
acids. Parallel mice studies indicate the molecular mechanism of TMAO suppression on 
RCT. A parallel mice study showed no alterations in total cholesterol or HDL-cholesterol 
in plasma, but in mice liver found an acceptable difference in Srb1 mRNA levels, a 
cholesterol transporter18. Cyp7a1 suppression in mice due to elevated TMAO 
concentrations leads to reduced bile acid synthesis and secretion, consequently promoting 
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atherosclerosis18,73-75. The upregulation of Cyp7a1 gene in mice results in upsurge of 
RCT and enhance the bile acid18,76-78. 
 
Fish Consumption 
 A randomized controlled crossover trial of animal-source foods showed that fish 
consumption produced higher circulating TMAO concentrations than either eggs or 
beef38,79,80. This study importantly demonstrated that TMAO production is a consequence 
of individual difference in the gut microbiome. Despite the possibility of higher 
circulating levels of TMAO, studies have shown that fish consumption which is rich in 
omega-3 fatty acids is associated with lower diastolic blood pressures and lower LDL-
cholesterol levels, without necessarily impacting HDL-cholesterol and triglyceride 
levels37. Conversely, a cohort of healthy women with no history of CVD found no 
protective effects of long-chain omega-3 fatty acids, tuna, dark fish, or alpha-linolenic 
acid on CVD outcomes43.  
 
Phosphatidylcholine / Choline 
Post-menopausal women tend to have lower choline levels due to the limited 
ability to synthesize de novo from phoshaptidylcholine29. This synthesis is carried out by 
hepatic phosphatidylethanolamine N-methyltransferase (PEMT) and this gene is under 
estrogenic control. Lower choline levels cause fatty liver or muscle damages more 
frequently in postmenopausal women or men81. Studies involving obese and overweight 
post-menopausal women consuming a Western diet had higher concentrations of free 
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plasma choline and TMAO. Further, higher intake of folate or methyl donors impacted 
the free choline pool whereas choline and betaine in the Western diet group had no effect 
on the free choline pool size29. In this study, homocysteine was also correlated with 
TMAO29. Other studies have shown inverse associations between higher choline intakes 
and plasma homocysteine levels82-85. Nevertheless, hyperhomocysteinemia has been 
linked with Western dietary patterns contributing to an increased free choline pool and 
promoting CVD risk86,87.  
Zheng et al. considered regular intake of phosphatidylcholine in both men and 
women free of CVD at baseline increased the risk of both all-cause mortality and CVD 
mortality48. Obeid et al. investigated cardiometabolic risk factors and found that higher 
HDL-cholesterol levels, plasma phospholipids and increased methylation capacity in 
humans was inversely associated with plasma TMAO concentration and choline levels88. 
The investigators further suggested that the inverse association of elevated TMAO 
concentrations and choline concentrations may result in hypomethylation 88.  
In a crossover feeding study of healthy young individuals, egg consumption led to 
improved biomarkers of CVD risk, including increased HDL-cholesterol, a decrease in 
the LDL /HDL-cholesterol ratio, and an intriguingly dose-dependent increase in plasma 
choline with no adjustments in plasma LDL-cholesterol or fasting plasma TMAO 
concentration44. In the same study, HDL-cholesterol increased by 3-4 mg/dL. Previous 
studies have estimated that a 1 mg/dL increase in HDL-cholesterol will reduce CVD risk 
by 2-4%, suggesting a 6-16% reduction in CVD risk in the above study associated with 
consumption of 1-3 eggs/day44,89. In another study, consuming 2-3 eggs/day resulted in 
 14 
an increase in both LDL-cholesterol and HDL-cholesterol particle size, with these larger 
cholesterol particles known to be less susceptible to oxidation and thus less 
atherogenic90,91. Further, a larger HDL-cholesterol molecule may favorably impact the 
risk of CVD due to enhanced RCT mediated by apolipoprotein A1 (Apo-A1) which 
facilitates the interaction of HDL-cholesterol and cellular cholesterol efflux 
transporters91.  
A trial of healthy individuals (both vegan/vegetarians and omnivores) 
supplemented with dietary choline led to a 10-fold increase in plasma TMAO levels for 
both groups, leading to a direct prothrombotic effect, with corresponding platelet 
aggregation92.  
 
L-Carnitine 
A study of overweight and obese post-menopausal women found that lower 
intakes of non-animal source foods such as whole grains, legumes, and cereals led to 
higher levels of LC; additionally, LC levels found to be higher among women with lower 
intakes of choline29. Further, LC was positively correlated with glucose and lipid 
metabolism, as expected from previous reports showing increases in glucose 
concentrations among obese individuals supplemented with carnitine while the opposite 
was true in lean individuals29,93. A cardioprotective effect of LC (vs. placebo) 
supplementation has been shown in patients with prevalent myocardial infarction; a 
systemic review and meta-analysis of 13 controlled trials found that LC supplementation 
led to a 27% reduction in all-cause mortality, 65% reduction in ventricular arrhythmias, 
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and 40% reduction in angina symptoms3,94. Further, a multiethnic population in Canada 
had no increased risk for CVD associated with serum levels of LC70. Lee et al. found 
improvements in lipid profiles (increases in HDL-cholesterol and Apo-A1, and small 
decreases in triglycerides levels) in patients with CAD who consumed 1000mg/day of 
supplemental LC57. Naini et al. found similar beneficial changes with a dose of 750 
mg/day of LC in hemodialysis patients95. Finally, an inverse correlation has been 
observed between antioxidant activity and LC supplementation in CAD patients57.  
 
Diet Patterns 
In another study by Obeid et al., they found no association between plasma 
TMAO levels and the strictness of adherence to a vegetarian diet60.Koeth et al. found 
lower levels of fasting TMAO at baseline in vegan and vegetarians as opposed to 
omnivores, but the synthesis of TMAO from oral consumption of carnitine-containing 
foods was significantly reduced in the long-term vegans/vegetarians18. In a healthy young 
German population there was no association between choline or betaine and TMAO 
concentrations following consumption foods from animal sources25. Haro et al. found 
alterations in protective gut microbiota with the consumption of two distinct healthy diets 
over a one year period in obese men with a history of coronary heart disease.  
The Mediterranean diet, rich in dietary fat, produced an abundance of Roseburia 
and Oscillospira (both of the phylum Firmicutes) and reduced the abundance of the 
genus Prevotella;  in contrast, a low-fat, high complex carbohydrate diet reduced the 
numbers of Roseburia while increasing Prevotella (Phylum: Bacteriodetes) and F. 
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prausnitzii (Phylum: Firmicutes)96. In a randomized intervention of either olive oil or 
nuts (vs. control) as a source of fat among 7447 older obese participants (the majority of 
whom had cardiometabolic dysfunction of some type), found that both intervention 
groups had 70 % lower CVD risks than the control97.  
The effects of protein-rich diets on CVD risk are controversial. A long-term 
cohort study found lower levels of both diastolic and systolic blood pressure (the leading 
cause of CVD) among healthy middle-aged adults consuming higher amounts of dietary 
protein diet independent of animal or plant source98. Higher protein intake in the highest 
tertile led to a 40% reduction in risk of hypertension. Systematic reviews and meta-
analyses of randomized controlled trials of the Mediterranean diet’s impact on vascular 
disease and mortality found a pooled 37% reduction in risk of major CV events (for both 
coronary and cerebrovascular events)99-102. Further, the overall risk of heart failure was 
reduced by 30% while there was no apparent effect on all-cause mortality and or CV 
mortality associated with the Mediterranean diet99-104. Casas et al. found that adherence to 
a Mediterranean diet with either extra-virgin olive oil or nuts as the fat source (compared 
with a lower-fat diet) led to improvements atheromatous plaque stability and vascular 
wall inflammation as well as reduction in LDL-cholesterol, diastolic and systolic blood 
pressures, and inflammatory and vascular adhesion markers (i.e., C-reactive protein, 
interleukin-6, soluble intercellular adhesion molecule, and P-selectin)105.  
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Microbes 
Mice who developed dyslipidemia from a Western diet were administered 3,3-
Dimethyl-1-butanol (DMB, an inhibitor of TMA formation); no effects of this treatment 
on dyslipidemia were found despite reduction in plasma TMAO concentration detected in 
both the mice fed a normal diet and those on a Western diet32. As discussed previously 
gut microbiota play and important role in the synthesis of TMAO from dietary 
precursors. Further, a Western diet has been shown to induce cardiac dysfunction, 
inflammation, and interstitial fibrosis in CD1 mice, which is reversal upon administration 
of DMB and associated with a lowering of plasma TMAO levels32. A study of humans 
undergoing a phosphatidylcholine challenge found that healthy adults given an antibiotic 
to eradicate gut microbes had suppressed TMAO production23.  
In addition, C57BL6/J mice supplemented with either choline or intact TMAO led 
to enhanced heart failure and increases in levels of brain natriuretic peptide, pulmonary 
edema, and myocardial fibrosis31. An additional study involving C57BL/6J mice fed a 
choline-rich diet displayed similar effects; with intact gut microbiota, elevated levels of 
TMAO were shown to lead to macrophage cell formation and intensified atherosclerotic 
plaque while in germ-free mice, TMAO was reduced thus improving atherosclerotic 
burden 17. Moreover, similar to the phosphatidylcholine challenge, a human study 
involving omnivores exhibited acceptable changes in postprandial endogenous TMAO 
and carnitine concentrations during an LC challenge18. Further, upon suppression of the 
gut microbiota with antibiotics, the LC challenge revealed nearly total suppression of 
endogenous TMAO and carnitine concentrations which, once antibiotic treatment was 
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concluded, led to recolonization of the microbiota and resumed TMAO formation18. 
Likewise, mice supplemented with LC frequently displayed an increased risk for CVD 
through the generation of TMAO derived from the alteration in gut microbiota; however, 
suppression of the gut microbiota reduced the production of TMAO production18. These 
results suggest a direct role of the gut microbiota in the development of the metabolite 
responsible for the increased risk of CVD events. A crossover feeding study concluded a 
diet rich in RS and low in total carbohydrates did not change postprandial fasting lipids, 
glucose, insulin, or lipoproteins; however, levels of TMAO increased in the high RS diet, 
suggesting that a diet rich in RS does not protect against TMAO-related cardiometabolic 
risk106. Noted is that RS produce short-chain fatty acids that have health benefits such as 
reduced the risk of developing gastrointestinal disorders, cancer, and cardiovascular 
disease107.   
In healthy young males, the ratio of high TMAO-producing microbes (Firmicutes 
to Bacteroidetes) is 2:1, whereas the ratio of low TMAO producers is 1:138. Gomez-
Arango et al. found higher amounts of the genus Odoribacter (Phylum: Bacteroidetes) 
capable of producing butyrate contributed to maintaining or reducing blood pressure in 
overweight and obese pregnant women13,108. Patients with atherosclerosis had microbial 
alterations in fecal samples as shown by increases in the genus Collinsella (Phylum: 
Actinobacteria) and reductions in levels of both Roseburia and Eubacterium (Phylum: 
Firmicutes) 109. Duncan et al. investigated fecal metabolites and microbiota of healthy 
obese individuals on varying carbohydrate-containing diets. A linear trend was observed 
between carbohydrate intake and butyrate concentration, with a 50% reduction in the 
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predominant SCFA, butyrate, seen between a maintenance carbohydrate diet and low-
carbohydrate diet. Further, as carbohydrate intake decreased between the groups, the 
butyrate-producing microbes, Roseburia, E. rectale, and bifidobacteria became less 
abundant110,111.  
Antibiotic treatment in rats suppresses the gut microbes and in vivo has been 
shown to reduce myocardial infarct size13,112,113. This indicates the causative role of the 
metabolites produced by the gut microbiota and increased risk of myocardial infarction. 
Marques et al. studied hypertensive mice fed a high fiber diet which led to favorable 
alterations in the gut microbiota and associated reductions in diastolic and systolic blood 
pressure, cardiac fibrosis, and left ventricular hypertrophy; these changes are likely to 
reduce risks of heart failure and hypertension114. Further, a high fiber diet increases the 
numbers of acetate-producing bacteria, and both high fiber diets and acetate 
supplementation have been linked with increases in numbers of Bacteroides acidifaciens 
(Phylum: Bacteroides)114.  
Romano et al. used an in vitro approach in identifying gut microbes utilizing 
choline for TMA production; eight species from the phyla Firmicutes and Proteobacteria 
consumed more than 60% of the choline for TMA production. The eight microbes 
utilizing choline but not LC in the human intestinal tract to synthesize TMA included the 
following: Anaerococcus hydrogenalis, Clostridium asparagiforme, Clostridium 
hathewayi, Clostridium sporogenes, Escherichia fergusonii, Proteus penneri, 
Providencia rettgeri, and Edwardsiella tarda115-117. Moreover, germ-free mice that are 
colonized with TMA-producing species showed an increase in serum TMAO levels as 
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opposed to mice that were not colonized with these microbes. Further, the choline 
bioavailability to the host was reduced when TMA-producing species were absent in the 
gut thus resulting in reduced TMAO levels.116.   
There is increasing evidence that dietary changes in the diversity of microbiota in the gut 
is impacting SCFAs. A study conducted in rural Malawi preschool aged children found 
changes in gut microbiota when subjects were given a RS containing diet; further SCFA 
levels were altered although the RS diet had no apparent anti-inflammatory properties118. 
Diet may also drive changes in gut microbiota through changes in SCFA production. A 
study of low-fat, high-fiber diets in African Americans demonstrated alterations in the 
gut microbiota as well as alterations in the SCFA profiles as well as the bile acids found 
in human fecal samples119. Pigs fed a diet rich in RS (arabinoxylan) produced a higher 
pool size of butyrate-producing species in fecal samples, including Faecalibacerium 
prausnitzii, Roseburia intestinalis, Blautia coccoides-Eubacterium rectale, 
Bifidobacterium spp. and Lactobacillus spp.120. Koeth et al. in an LC challenge study 
found that omnivores (vs. vegetarians) had in higher numbers of the genera 
Clostridiaceae and Peptostreptococcaceae but lower numbers of Lachnospira and 
Sporobacter appeared18,115. 
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DISCUSSION 
 Gut microbiota plays a crucial role in the development of TMAO through dietary 
precursors including phosphatidylcholine, choline, betaine, and LC. Likewise, intact 
TMAO may be derived from marine sources. Dietary precursors are first converted into 
TMA in the gut and transferred to the liver for the hepatic enzyme (primarily hepatic 
enzyme FMO3 in both human and animals) to aid in the synthesis of TMAO. The risk of 
CVD rises as plasma TMAO concentration increases contributing to the suppression of 
the RCT pathway, affecting net cholesterol removal from peripheral tissues back to the 
liver for excretion via bile acids. In addition to suppression of the RCT pathway, a 
reduction in bile acids occurs from the down-regulation of the key bile acid synthesizing 
enzyme Cyp7a1 when levels of TMAO are elevated. 
The increased risk of CVD highly correlates with increasing levels of circulating 
plasma TMAO. Accounting for potential confounding variables such as age, sex, BMI, 
smoking, energy intake, and other factors associated with diet or systemic diseases, 
strengthens the association between TMAO and risk of CVD. Dietary patterns play 
critical roles in the evolution of CVD, and some of these are beneficial and others, 
detrimental. A Western diet has been linked with development of dyslipidemia while 
adherence to a Mediterranean diet reduces the risk of major CVD events. Dose-dependent 
response of choline intake from eggs has been associated with improvements in 
cardiometabolic biomarkers while exhibiting no changes in fasting plasma TMAO. 
Choline derived from eggs has shown to increase lipoprotein particle size for HDL and 
LDL-cholesterol causing the rate of RCT to increase.  
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Choline in combination with betaine plays an important role in methyl 
metabolism. Choline oxidation via choline dehydrogenase may also produce betaine, as a 
key constituent in the remethylation of homocysteine through BMHT. Both betaine and 
its intermediary metabolite DMG are biomarkers for CVD. Betaine concentrations in 
humans are associated with different health outcomes depending on the individual's 
systemic health. Low betaine levels in healthy individuals have been linked with an 
increased risk for CVD, whereas patients with diabetes have a greater CVD risk with 
high betaine concentrations. The long-term intake of both choline and betaine and its 
involvement in methyl metabolism has been linked with reductions in homocysteine 
levels, which in turn will lower the risk of CVD. 
LC is critical for the transport of long chain fatty acids into the mitochondria for 
oxidation and energy production. Diets higher in meats raise levels of LC. The 
cardioprotective effects of LC in patients with a history of CVD may be a result of 
changes in lipid profiles and antioxidant activity. Unexpectedly, fish consumption, with 
its high levels of intact TMAO leading to increased concentrations of TMAO in humans, 
provides protection against CVD risk. This protective effect is thought to be due to high 
levels of healthy dietary fats, particularly omega-3 fatty acids, and their effects on lipid 
profiles.  
Consumption of the dietary precursors involved in TMA production during 
antibiotic therapy suppresses gut microbiota, thereby decreasing TMA synthesis and 
resulting in a reduction in circulating concentrations of TMAO. Microbial communities 
in the phyla Firmicutes and Bacteriodetes specifically the species Roseburia spp. and 
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Eubacterium spp. are major butyrate producers that provide protective effects against 
CVD by lowering the ratio of Roseburia/Bacterium. RS changes the gut microbial 
community favoring the synthesis of SCFA which provides protective effects against 
CVD. 
 Animal models and human studies have shown distinct effects in groups with and 
without CVD when dietary phosphatidylcholine, choline, betaine, carnitine, or intact 
TMAO supplementation is consumed. In two distinct studies, first in cardiac patients and 
secondly in atherosclerosis prone mice, the CVD burden was enhanced as indicated by an 
increase in atherosclerotic plaque when dietary precursors for TMAO synthesis were 
derived from the diet, and additionally showed no changes in the lipid profiles. Recently, 
the intake of fish has come under scrutiny for its contribution to marked increases in 
circulating concentrations of TMAO compared with that seen from consuming eggs 
(providing dietary choline) or beef (with a high content of carnitine). Fatty fish, rich in 
omega-3-fatty acids has been shown to provide protective effects against CVD risk in 
numerous studies but many other reports have found no impact on CVD risk. Egg 
consumption is also controversial. Phosphatidylcholine and choline both present in high 
amounts in eggs revealed differing outcomes. Regular dietary intake of 
phosphatidylcholine increased atherosclerotic plaques as well as all-cause mortality and 
CVD mortality in humans free of CVD at baseline. Choline, which is involved in the 
methylation of homocysteine into methionine, is considered protective against CVD due 
to its role in lowering homocysteine. The increased choline concentrations may be 
confounded by the higher TMAO concentration resulting from synthesis involving gut 
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microbiota. Further, choline may be inversely related to TMAO circulating 
concentrations since high choline content disrupts methyl donation.   
The impact of LC on impact health outcomes differed by an individual’s systemic 
health and level of obesity. Lean subjects tended to have favorable associated with LC 
supplementation such as reductions in glucose concentrations, while the opposite was 
seen in obese subjects. Supplementation with LC in patients with myocardial infarction 
improved the cardiometabolic status as shown by reductions in risk factors for CVD and 
diabetes. Additionally, LC supplementation has been shown to improve lipid profiles 
among individuals with prevalent CAD.  
 Mechanisms of action for TMAO’s impact on CVD risk involves changes 
associated with cholesterol and sterol metabolism leading to foam cell formation and 
enhancement of scavenger receptors, CD36 and scavenger receptor-A, on macrophages 
affecting the rate of cholesterol influx and efflux17,18,24,121,122. The RCT pathway is a 
critical component in the prevention of atherosclerosis in both humans and animals and 
involves transporting cholesterol to the liver for the synthesis and excretion as bile acid. 
Large intakes of dietary TMAO, LC, and choline degrade the RCT pathway leading to a 
reduced bile acid pool size and elevated levels of non-HDL-cholesterol in circulation. 
TMAO may alter sterol metabolism through the impact of TMAO on cholesterol 
transport, Abca1, Srb1, and Abcg118. Both Abca1 and Abcg1 increase significantly with 
TMAO. Srb1 displays minimal changes in mRNA levels. Bile acid transports in the liver, 
Oatp1, Oatp4, Mrp2, and Ntcp and bile acid enzymes responsible for the synthesis, 
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Cyp7a1, and Cyp27a1, decrease with TMAO supplementation, driving alterations in bile 
acid pool size and composition18. 
The review highlights the multiple human and animal trials addressing the 
associations between diet, dietary precursors, gut microbiota composition, and their 
derived metabolite TMAO on the presence or absence of CVD. It also highlights some of 
the contradictory results and identifies areas needing further study. 
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CHAPTER 2– Framingham Offspring Study – Animal and Plant Protein Intake 
and Dietary Lipids  
INTRODUCTION 
Lipid levels and lipid particle composition and size play a role in the pathogenesis 
of CVD. Elevated levels of LDL-cholesterol and triglycerides as well as lower levels of 
HDL-cholesterol are predictors of CVD risk. In addition, studies have shown that an 
abundance of small dense LDL particles to be independently associated with the 
increased risk of CVD123-127. 
A dietary pattern that is low in trans-fat has shown to provide cardioprotection by 
reducing total cholesterol, LDL-cholesterol, triglycerides, and cholesterol: HDL-
cholesterol ratio123,128. For years, saturated fatty acids were also believed to be associated 
with elevated CVD risk but recent meta-analyses have concluded that there is no 
association between saturated fats and heart disease129. However, other meta-analyses 
have concluded that replacement of saturated fats with poly-unsaturated fats will reduce 
LDL-cholesterol130. Further, the carbohydrate content of the diet is also a critical 
determinant of lipid level. 
Previous reports have also shown that alterations in the content of fat and 
carbohydrate in a diet can alter LDL particle diameter123,131,132. There is increasing 
recognition, however, that it is not possible to change a single element in the diet. For 
example, a low-fat dietary regimen to reduce CVD risk is usually is compensated for with 
an increase in dietary carbohydrates resulting in deleterious reductions in the LDL 
particle size, and thus leading to increased small dense LDL particles which contribute to 
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CVD risk124,133 . Hypertriglyceridemia, a condition involving elevated levels of serum 
triglyceride concentration leads to several systemic conditions including alterations in 
lipoprotein-lipid profiles134,135. Specifically, hypertriglyceridemia lowers HDL 
cholesterol and leads to an increase in the prevalence of small, dense LDL particles 
(LDL-P)136. Secondly, higher triglycerides lead to elevations in levels of VLDL-
cholesterol and the number VLDL particles (VLDL-P), leading to reductions in HDL-
cholesterol levels and HDL-P concentrations134,135.  
A pattern of atherogenic lipid levels called atherogenic dyslipidemia (also known 
as the lipid triad), is characterized by elevated fasting triglyceride levels137, increased 
numbers of small, dense LDL-P, and reductions in HDL-cholesterol138; it is strongly 
correlated with elevated CVD risk139. Individuals with CVD have also been shown to 
have a predominance of smaller HDL-cholesterol particles, which are prone to 
malfunctioning and susceptible to catabolism90,140. Small, dense HDL-cholesterol has 
been associated with metabolic syndrome (group of risk factors for CVD and type 2 
diabetes) whereas larger HDL-P sizes are inversely associated with CVD risk90,140-142.  
Dietary and lifestyle factors are the foundation for reversing the lipid triad135. 
Disruptions in carbohydrate metabolism result from increased glycemic load, added 
sugars, and diets rich in refined starches. Some studies have shown that cardiometabolic 
health markers may be improved by substituting refined starches and added sugars with 
egg proteins and unsaturated fats in overweight and obese hypertriglyceridemic 
individuals135. Men and women with metabolic syndrome have been shown to have 
improvements in atherogenic dyslipidemia with the consumption of eggs and a 
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moderately restricted carbohydrate diet141. Soy protein intake has shown to increase LDL 
particle size and reduce LDL-cholesterol levels123. The objective of this study is to 
evaluate the association between intakes of dietary protein from both animal and plant 
sources and lipid profile changes. 
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METHODS 
Study Sample 
The Framingham Offspring Study, a prospective cohort commenced in 1971 
involving 5,124 Caucasian subjects who were descendent of the original Framingham 
Heart Study cohort143. At each examination, the following types of data were collected: 
12-hour fasting blood samples, urinalysis, anthropometric measures, medical history, and 
lifestyle habits. Subjects were 53% female with a mean age of 51 years. The first two 
examinations were conducted eight years apart (1971-1975, 1979-1983), followed by 
recurring examinations at four-year intervals (1983-1987, 1987-1991, 1991-1995, 1995-
1998, 1998-2001, 2005-2008). Dietary data used in this report were collected during 
examination year 3. Follow-up continued through exam 8, giving a total of up to 20 years 
of data on lipid levels.	
Subjects were included in the current analyses if the following criteria were met: 
(1) attended the third and fourth examination cycle (1987-1991), (2) were 30-<75 years 
of age at exam 3 (3) had no history of prevalent cancer, prevalent coronary heart disease, 
diabetes, or taking lipid-lowering medications, (4) had dietary data at exam 3 for animal 
protein, plant protein, energy intake, egg servings, red meat servings, lean red meat 
servings, processed meat, poultry servings, fish servings, dairy servings, short-chain fatty 
acids, % calories from fat, carbohydrates, and protein, total fruit and vegetable intake, 
and dietary fiber, (5) no extreme intakes of energy, protein, or protein-related foods in 
diet, (6) were not missing data on lipids, (7) had complete data for all confounders 
included in the final models (e.g., sex, education, age, physical activity, cigarettes per 
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day, current smoking, pack-years, television, and prevalent high blood pressure) and (8) 
serum triglyceride concentration <400 mg/dL at baseline.  
	
Lipid	and	Lipoprotein	Particle	Measurements		
Blood samples from those who fasted for at least 8 hours were added to 0.1% 
ethylenediaminetetraacetic acid and centrifuged to separate the blood plasma and plasma 
lipid concentrations144. Automatic enzymatic methods previously described were 
performed to separate the plasma lipids including cholesterol, triglycerides, and HDL-
cholesterol145. All samples were collected and analyzed in a blinded fashion, so that 
investigators did not know which biochemical, and NMR analysis belonged to which 
subject. Serum triglycerides >400mg/dL were excluded144. NMR spectroscopic assay 
derived samples of lipoprotein particle profiles in 1995 were used and described 
previously144. The concentration of VLDL and LDL are summed to give the total VLDL 
(VLDL-P) and LDL (LDL-P) particle concentrations obtained from nuclear magnetic 
resonance (NMR) signals144. The total atherogenic particle concentration was also 
examined by the sum of LDL-P and VLDL-P144. VLDL and LDL diameters were each 
summed for its subclass and multiplied by its relative mass percentage estimated from the 
amplitude of its NMR signal to give the LDL-P size (nm diameter)144. LDL-cholesterol 
was divided by LDL-P to provide the cholesterol content in the LDL-P thus 
approximating the cholesterol content in each LDL-P144. Interassay coefficients of 
variation are <3% and <0.5% for VLDL-P and LDL-P for the LDL size144.  
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Potential Confounding Variables 
Potential confounding variables included both fixed factors from time of the 
dietary assessment (e.g., sex, education level) as well as potentially change factors such 
as smoking or physical activity, age, sex, and education level were included in all models. 
Cigarette smoking in Framingham was assessed at each exam as current smoking status 
(yes or no at exam 1) and the number of cigarettes smoked per day; the number of pack-
years smoked up to that point (number of packs per day smoked x number of years of 
smoking) was calculated including data for non-smokers who were asked if they had 
previously smoked, and if so, what years they had started and stopped.  
Physical activity as assessed (exam 2 and exams 4-7) by asking each subject to 
report the number of hours per day and per week spent in sports or recreational activities 
of varying intensities classified as vigorous, moderate, and light activity. Vigorous 
activity was classified as heavy house work or intensive exercise. Moderate activity 
classified as normal house work, climbing stairs and light sports. Further, Subjects were 
also asked number of hours spent sitting and sleeping. The physical activity index score 
was calculated using the vigorous and moderate activities by taking the estimated oxygen 
consumption. To calculate the estimated oxygen consumption, a numeric weight for each 
activity was multiplied by the length of time spent in the activity.  
BMI measurements were calculated with adjusting the height to the next lowest ¼ 
inch and weight to the nearest pound using a beam balance146. To avoid effects of height 
due to age, the mean height measures were recorded at <60 years of age. BMI range of 
25-<30 kg/m2 is classified as overweight and ≥30 kg/m2 as obese. 
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A number of dietary factors were assessed as potential confounders measured at 
exams 3 and 5 with dietary records. These include carbohydrate consumption, dietary 
fiber, intake of fruits and vegetables, dairy products. The My Pyramid Equivalents 
Database 2.0 for USDA Survey Foods (2003-2004) was used to derive the food 
intakes147. Alcohol intake was assessed at each exam by self-report by the number of 
drinks (beer, wine, cocktail) consumed per day or per week. Total grams of alcohol per 
day were included in the final multivariable models. Alcohol consumption status was also 
recorded based on current drinker, past drinker, abstainer, or abuser. Alcohol use 
frequency (lifetime abstainer, past drinker, occasional drinker, regular drinker) and 
alcohol amount (light, moderate, heavy) was measured.  
 
Statistical Methods 
The objective of this analysis was to evaluate the effects of total protein as well as 
animal and plant proteins on lipid levels and lipid numbers and particle sizes in adults, 
ages 30 to 74 years of age at baseline. We first explored the distribution of animal and 
plant protein consumption among adults. Since dietary protein intake is associated with 
total energy intake and since energy intake is associated with total body weight, it is 
important to consider protein intake for each subject in relation to their energy intake or 
body size. We chose to express protein in relation to body size since it is measured with 
less error than is energy intake. Thus, protein intake will be expressed in two ways for 
these analyses: grams per kilogram per day of body weight and weight-adjusted protein 
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intake using the residual method. The protein residual method accounts for differences in 
body weight. 
It is unclear whether the relations between protein consumption and lipid levels 
and particle size and/or number are linear. Therefore, we will explore the shape of the 
relation using sensitivity analyses to guide the classification of protein intake. One way 
analysis of variance may be used to compare mean lipid values across categories of 
protein intake. Since lipid particle size and number are available only from exam 4, 
analysis of covariance (ANCOVA) will be used to adjust these means for potential 
confounding by the factors described above. Since there are multiple measures of lipid 
levels, we took advantage of the repeated measures and used longitudinal mixed models 
with a protein consumption*time interaction term to compare lipid levels over time 
according to protein intake. 
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RESULTS 
 Table 1 shows the characteristics of the Framingham Offspring Study for subjects 
with lower, moderate, or higher intakes of animal protein in their diets while table 2 
shows the same characteristics according to intakes of plant proteins. Those with the 
lowest intakes of both animal and plant proteins had somewhat higher BMIs at baseline 
and were slightly less active. While those consuming the most animal protein were more 
likely to smoke, the opposite was true for plant protein.  
 
Table 1. Characteristics of the Framingham Offspring Study subjects according to 
tertiles of intake of animal protein in the diet  
 
  
All subject tertiles of weight-adjusted animal protein, 
exam 3 
Baseline (Exam 3) 
Variables 
Lowest Tertile Middle Tertile Highest Tertile 
  Mean SD Mean SD Mean SD 
Age,	years)	 50.0	 9.34	 49.6	 9.57	 47.8	 9.25	
Weight,	kg	 73.7	 15.78	 71.8	 14.97	 74.0	 14.77	
Height,	cm	 167.2	 8.82	 167.7	 8.83	 170.4	 9.42	
Body	Mass	Index,	kg/m2	 26.3	 4.65	 25.4	 4.18	 25.3	 3.79	
Diastolic	BP,	mm	Hg	 79.0	 9.19	 78.7	 9.04	 77.8	 9.17	
Systolic	BP,	mm	Hg	 123.5	 15.56	 123.3	 16.22	 120.8	 15.30	
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Cigarettes	per	Day		 4.9	 10.97	 4.6	 10.84	 5.6	 11.84	
Physical	Activity	Index	 11.7	 7.64	 11.7	 7.40	 12.4	 7.80	
Energy,	kcals/day	 1549	 444	 1848	 491	 2238	 582	
Protein,	gm/day	 55.4	 12.60	 74.5	 12.28	 100.1	 19.05	
Animal	protein,	gm/day	 35.9	 8.89	 53.4	 7.94	 77.4	 15.10	
Plant	protein,	gm/day	 18.6	 7.96	 20.0	 7.80	 21.5	 7.93	
Total	carbohydrate,	
gm/day	
185.8	 64.37	 202.3	 68.07	 227.4	 75.74	
Total	fat,	gm/day	 62.1	 21.80	 77.0	 25.80	 95.4	 31.54	
Alcohol,	gm/day	 7.6	 12.36	 10.7	 16.47	 13.5	 18.48	
Dietary	fiber,	gm/day	 13.7	 5.89	 14.8	 5.54	 16.1	 6.49	
Total	Cholesterol,	mg/dL	 215.0	 41.16	 209.7	 39.19	 207.3	 38.13	
HDL,	mg/dl	 52.6	 15.43	 53.4	 14.99	 51.3	 13.96	
LDL,	mg/dL	 140.0	 37.60	 134.3	 35.27	 134.5	 34.92	
Triglycerides,	mg/dl	 112.8	 71.40	 112.5	 102.60	 110.3	 78.09	
Log	of	Triglycerides,	mg/dl	 4.6	 0.56	 4.5	 0.56	 4.5	 0.57	
 
  
 36 
Table 2. Characteristics of the Framingham Offspring Study subjects according to 
tertiles of intake of plant protein in the diet  
  
 
Tertiles of weight-adjusted plant protein, exam 3 
Baseline (Exam 3) 
Variables 
Lowest Tertile Middle Tertile Highest Tertile 
	 Mean SD Mean SD Mean SD 
Age,	years)	 49.2	 9.31	 49.1	 9.31	 49.1	 9.68	
Weight,	kg	 74.4	 16.47	 71.1	 14.71	 74.0	 14.14	
Height,	cm	 166.7	 9.09	 167.3	 8.66	 171.4	 8.93	
Body	Mass	Index,	kg/m2	 26.6	 4.83	 25.2	 3.99	 25.1	 3.63	
Diastolic	BP,	mm	Hg	 78.8	 9.30	 78.6	 9.23	 78.1	 8.90	
Systolic	BP,	mm	Hg	 123.0	 16.08	 122.7	 15.44	 122.0	 15.68	
Cigarettes	per	Day		 6.9	 12.77	 4.4	 10.47	 3.8	 10.03	
Physical	Activity	Index	 11.7	 7.41	 11.8	 7.16	 12.2	 8.24	
Energy,	kcals/day	 1476	 407	 1853	 453	 2306	 547	
Protein,	gm/day	 65.0	 19.39	 75.2	 20.75	 89.8	 23.78	
Animal	protein,	gm/day	 51.2	 18.46	 55.3	 19.86	 60.2	 21.49	
Plant	protein,	gm/day	 12.9	 2.75	 18.8	 2.52	 28.5	 7.32	
Total	carbohydrate,	
gm/day	
149.4	 44.11	 201.9	 52.17	 264.1	 64.17	
Total	fat,	gm/day	 62.5	 22.42	 77.7	 26.29	 94.4	 31.47	
Alcohol,	gm/day	 10.2	 16.01	 10.1	 14.46	 11.6	 17.78	
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Dietary	fiber,	gm/day	 10.6	 3.66	 14.1	 3.88	 20.0	 6.05	
Total	Cholesterol,	mg/dL	 212.8	 40.03	 212.7	 39.76	 206.6	 38.84	
HDL,	mg/dl	 52.6	 15.33	 53.4	 15.05	 51.3	 14.02	
LDL,	mg/dL	 137.8	 36.70	 137.1	 35.70	 134.0	 35.65	
Triglycerides,	mg/dl	 114.3	 75.07	 113.4	 100.11	 108.1	 77.61	
Log	of	Triglycerides,	mg/dl	 4.6	 0.56	 4.5	 0.57	 4.5	 0.56	
 
 
In Figure 1, it is evident that the LDL cholesterol levels are higher at exam 3 than 
at subsequent exams, regardless of protein intake. These trends may reflect differences in 
treatment of LDL at different exams since lipid-lowering drugs became more frequently 
used over time. At every exam, however, subjects with the highest intakes of animal 
protein had the lowest LDL-C levels. At the baseline exam, subjects with the lowest 
protein intake had LDL-C levels that were 5.6 mg/dL higher than those with the highest 
intakes. While the mean differences vary over the years, by exam 8, those with the lowest 
protein intake still had LDL-C levels that were 6.3 mg/dL higher than those in the highest 
tertile of animal protein intake. 
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Figure 1. LDL Cholesterol according to Weight-adjusted Animal Protein at Exams 
3-8 (All Subjects) 
 
The changes in LDL-cholesterol associated with intake of animal protein 
stratifying by sex are shown in Figures 2 and 3. Figure 2, in men, displays a decreasing 
trend in LDL-cholesterol as tertiles for animal protein intake increases over each exam. 
Men at baseline had an LDL-cholesterol level that was 4.8 mg/dL higher in the lowest 
tertile than in the highest tertile of intake. By exam 8, men had LDL-cholesterol levels 
8.3 mg/dL higher in the lowest tertile group compared with the highest tertile. 
In Figure 3, women exhibited a similar trend to men with decreasing LDL-
cholesterol concentrations as animal protein intake tertiles increased over the exams. 
These results were less stable among women, particularly at exams 6 and 7.  At baseline 
women had an LDL-cholesterol being 7.6 mg/dL higher in the lowest animal protein 
tertile compared with the highest tertile. The LDL levels associated with dietary protein 
at exam 8 for women were not significantly different. 
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Figure 2. LDL Cholesterol according to Weight-adjusted Animal Protein at Exams 
3-8 (Men Only) 
 
 
 
Figure 3. LDL Cholesterol according to Weight-adjusted Animal Protein at 
Exams 3-8 (Women Only) 
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In Figure 4, the effects of plant protein on LDL-cholesterol are assessed. The 
highest intake of plant protein at each exam was associated with the lowest LDL-
cholesterol concentrations. The differences between the lowest and highest plant protein 
intakes were associated with a mean difference of 2.1 mg/dL at baseline and 7.6 mg/dL at 
exam 8.  
 
 
Figure 4. LDL Cholesterol according to Weight-adjusted Plant Protein at Exams 3-8 
(All Subjects) 
 
When plant protein intakes were stratified by sex (Figure 5), we found that the beneficial 
effects among men were inconsistent. The differences between the lowest and highest 
adjusted mean LDL levels were small and in some cases, showing effects in opposite 
directions. Thus plant protein intake seems to be unassociated in general with LDL levels 
in men. In women, however, (Figure 6), there was a consistent trend with those in the 
lowest tertiles of plant protein intake having the highest concentration of LDL-C when 
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compared with those in the highest tertile at each examination. The mean difference in 
baseline concentration of LDL was 4.1 g/dL and at exam 8, it was 5.8 mg/dL. 
 
 
 
Figure 5.  LDL Cholesterol according to Weight-adjusted Plant Protein at Exams 3-
8 (Men Only) 
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Figure 6.  LDL Cholesterol according to Weight-adjusted Plant Protein at Exams 3-
8 (Women Only)  
 
 
Figure 7. HDL Cholesterol according to Weight-adjusted Animal Protein Intakes at 
Exams 3-8 (All Subjects) 
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In Figure 7, it is evident that HDL-cholesterol levels increase from baseline 
examination 3 to exam 8. At each exam, the highest tertile of the intake for animal 
protein showed the highest HDL-cholesterol content. At the baseline examination, the 
highest tertile of animal protein intake was 1.66 mg/dL higher than the lowest tertile. By 
exam 8, the overall HDL-cholesterol concentration was higher than at previous exam but 
the mean difference according to animal protein intake was quite low. 
 
 
Figure 8. HDL Cholesterol according to Weight-adjusted Animal Protein Intakes at 
Exams 3-8 (Men Only) 
 
Figure 8 shows that baseline concentrations of HDL-cholesterol in men were 2.80 
mg/dL higher in the highest tertile of animal protein intake, while at exam 8, they were 
3.59 mg/dL higher. Women (Figure 9) had much higher HDL-cholesterol levels over 
time than men. At baseline, the highest animal protein tertile was associated with an HDL 
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concentration of 1.70 mg/dL higher than the lowest tertile. By the end of follow-up, the 
mean difference was only 0.40 mg/dL between the lowest and highest tertiles. 
 
Figure 9.  HDL Cholesterol according to Weight-adjusted Animal Protein Intakes at 
Exams 3-8 (Women Only) 
 
 
Figure 10. HDL Cholesterol according to Weight-adjusted Plant Protein Intakes at 
Exams 3-8 (All Subjects) 
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Once stratified by sex, the HDL-cholesterol also showed a similar trend in both 
men and women with increasing HDL-cholesterol size over the examination periods. In 
Figure 8, baseline concentration of HDL-cholesterol in men was 2.80 mg/dL higher in the 
highest tertile of animal protein intake while at exam 8, it was 3.59 mg/dL higher. 
Women (Figure 9) had much higher HDL-cholesterol levels over time than men. At 
baseline, the highest animal protein tertile was associated with an HDL concentration of 
1.70 mg/dL higher than the lowest tertile. By the end of follow-up, the mean difference 
was only 0.40 mg/dL between the lowest and highest tertiles. 
Plant protein intake and HDL-cholesterol are shown in Figure 10. HDL levels at 
the baseline exam were 2.90 mg/dL higher in the highest plant protein tertile (compared 
with lowest). At exam 8, there is a greater increase in the HDL-cholesterol content 
revealed by the highest tertile having 3.04 mg/dL higher HDL than those in the lowest 
tertile. Upon stratification by sex, (Figure 11), there were still strong beneficial effects of 
plant protein intake on HDL-C in men as well as women (Figure 12).  
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Figure 11. HDL Cholesterol according to Weight-adjusted Plant Protein Intakes at 
Exams 3-8 (Men Only) 
 
 
Figure 12. HDL Cholesterol according to Weight-adjusted Plant Protein Intakes at 
Exams 3-8 (Women Only) 
In Figure 13, it is evident that over the examination period there was an increase 
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the sex-stratified analyses, men with the highest intakes of animal protein had the lowest 
triglyceride levels (Figure 14). The effects in women were weaker (Figure 15). 
 
Figure 13. Log of Triglycerides according to Weight-adjusted Animal Protein 
Intake at Exams 3-8 (All Subjects) 
 
Figure 14. Log of Triglycerides according to Weight-adjusted Animal Protein 
Intake at Exams 3-8 (Men Only) 
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Figure 15. Log of Triglycerides according to Weight-adjusted Animal Protein 
Intake at Exams 3-8 (Women Only) 
 
Plant protein was associated with an increasing trend in the log of triglycerides 
over the 6 exams. However, the changes associated with increased plant protein intake 
were slightly stronger than those for animal protein intake. In Figure 16, at baseline, the 
lowest tertile of intake was 0.09 mg/dL higher (on a logarithmic scale) than that seen with 
the highest level of plant protein intake. By exam 8, the mean difference in log of 
triglycerides was 0.14 mg/dL. Upon stratification in Figure 17, men in the lowest tertile 
of plant protein intake had baseline log of triglycerides that was 0.11 mg/dL higher than 
that seen in those with highest tertile of intake. The effects at exam 8 were somewhat 
stronger. In Figure 18, women also had a 0.11 mg/dL higher log of triglycerides at 
baseline in the lowest tertile of intake. By examination 8, the log of triglyceride was 0.16 
higher in the lowest tertile compared with the highest tertile of intake.  
 
4.404.45
4.504.55
4.604.65
4.704.75
4.804.85
4.90
exam	3 exam	4 exam	5 exam	6 exam	7 exam	8
Lo
g	
(T
ri
gl
yc
er
id
es
)
Lowest	tertileMiddle	tertileHighest	tertile
 49 
 
 
 
Figure 16. Log of Triglycerides according to Weight-adjusted Plant Protein Intake 
at Exams 3-8 (All Subjects) 
 
 
Figure 17. Log of Triglycerides according to Weight-adjusted Plant Protein Intake 
at Exams 3-8 (Men Only) 
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Figure 18. Log of Triglycerides according to Weight-adjusted Plant Protein Intake 
at Exams 3-8 (Women Only) 
 
 
 
Figure 19. Total Cholesterol, Exams 3-8, according to Weight-adjusted Animal 
Protein Intake (All Subjects) 
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In Figure 19, the overall total cholesterol concentrations varied over the 
examination period. In each exam, the higher animal protein tertiles were linked with 
decreased levels of total cholesterol. At baseline, the mean difference from low to high 
animal protein intakes was 5.16 mg/dL and by exam 8, the mean difference was 6.68 
mg/dL. In the sex-stratified results in Figure 20 and 21, the beneficial effect of animal 
protein intake was more consistent among men than among women.  
In Figure 22, a similar trend is seen for plant protein consumption and total 
cholesterol when compared with animal protein. At each exam, those with higher protein 
intakes had lower total cholesterol concentrations. At baseline, the mean difference in 
total cholesterol level was small (0.97 mg/dL lower in the highest vs. lowest tertile of 
plant protein intake). By exam 8, there was a much larger mean difference (7.94 mg/dL). 
Upon stratification by sex, Figure 23 shows that the results among men were weak and 
variable over the follow-up period. In Figure 24, women displayed a much greater 
difference in total cholesterol associated with plant protein intake than did men. At 
baseline and at the end of follow-up, women in the highest tertile of plant protein intake 
had total cholesterol levels that were 4-5 mg/dL lower than those in the lowest tertile of 
plant protein intake. 
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Figure 20. Total Cholesterol, Exams 3-8, according to Weight-adjusted Animal 
Protein Intake (Men Only) 
 
Figure 21. Total Cholesterol, Exams 3-8, according to Weight-adjusted Animal 
Protein Intake (Women Only) 
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Figure 22. Total Cholesterol, Exams 3-8, according to Weight-adjusted Plant 
Protein Intake (All Subjects) 
 
 
Figure 23. Total Cholesterol, Exams 3-8, according to Weight-adjusted Plant 
Protein Intake (Men Only) 
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Figure 24. Total Cholesterol, Exams 3-8, according to Weight-adjusted Plant 
Protein Intake (Women Only) 
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DISCUSSION 
 
 In this study, we found that both animal and plant proteins were inversely 
associated with total cholesterol and LDL-cholesterol. Over 20 years of follow-up, those 
in the highest tertiles of protein intake generally had the lowest total and LDL-cholesterol 
levels. Changes associated with the LDL-cholesterol profile when greater amounts of 
either animal protein or plant protein were consumed led to similar decreases in LDL-
cholesterol with increasing tertiles of protein intake at each follow-up exam. Among men, 
the inverse relationship was stronger between intakes of animal protein and LDL-C as 
well as total cholesterol. Among women, however, the relationship between plant 
proteins and LDL-C (as well as total cholesterol) was stronger for plant proteins. This 
could be in part a result of the fact that animal protein consumption was higher among 
men and more strongly correlated with total protein intake. Women in contrast had higher 
plant protein intakes (data not shown).  
Interestingly, though the HDL-cholesterol increases with both types of protein, 
animal protein tends to plateau at exam 6 and exhibits a downward trend at exams 7 and 
8 for changes in the concentration. Plant protein proceeds to increase the content of HDL-
cholesterol over the examination period. The changes associated with protein intake on 
HDL-cholesterol in men appeared to be similar regardless of the type of protein 
consumed.  However, in women, plant protein was more strongly positively associated 
with HDL-C levels. The effects of protein on HDL seemed to be similar across the exam 
visits. Overall, both animal and plant protein intakes were inversely associated with (log-
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transformed) triglyceride levels. As before, the effects of animal protein were stronger in 
men and the effects of plant protein were stronger in women. 
Hypertriglyceridemia and atherogenic dyslipidemia occur from unfavorable 
changes associated with lipid profiles. An upturn in serum triglycerides, total cholesterol, 
LDL-cholesterol, and reduction in HDL-cholesterol concentration raises the risk of CVD. 
Dietary and lifestyle changes are key to preventing and reversing these abnormalities 
before pharmaceutical drugs are implemented. Dietary patterns that have been shown to 
aid in treating the lipid triad involves reducing saturated and especially trans fats as well 
as simple carbohydrates123,128. Alternatively, dietary approaches targeting increased 
MUFAs and PUFAs (especially as replacements for saturated fats) derived from dietary 
patterns such as the DASH diet and Mediterranean diet patterns have been shown to 
improve cardiometabolic risk factors148. In general, the evidence related to fatty acids and 
lipid levels is inconsistent. While higher saturated fatty acids may increase LDL 
cholesterol, it also increases HDL149. In addition, SFAs from dairy-derived sources have 
been associated with fewer small dense lipid particles, thereby reducing the risk of 
atherosclerosis150. 
The impact of dietary protein is often overlooked when preventive and therapeutic 
strategies are used to target lipid profiles. A meta-analysis of high protein, low-fat diets 
found no association overall with LDL-C or total cholesterol but an inverse association 
with triglyceride levels151. In this study, the intake of dietary animal protein and plant 
proteins correspond favorably with altered the lipid profiles. Since both animal and plant 
proteins were beneficial, these results may support those of other studies suggesting that 
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total protein may be even more important than a particular protein from either animal or 
plant sources.  
Some studies suggest that different food sources of dietary protein have different 
effects on lipid levels. As mentioned, protein (e.g., whey protein) from dairy sources may 
alter lipid levels or lipid particle sizes150. A previous randomized clinical trial evaluated 
the changes in lipid profiles from dietary protein derived from egg consumption135. Maki 
et al. found positive changes in the majority of the lipid profiles; egg protein revealed a 
significant reduction of triglycerides and VLDL-cholesterol content.  Further, reductions 
were also observed in total cholesterol, LDL-cholesterol, and non-HDL-cholesterol, 
although there were reductions in HDL-cholesterol as well135. Aadland et al. conducted a 
dietary study involving healthy adults and found that the intake of lean-seafood lowered 
the content of serum triglycerides while also preventing VLDL-P from increasing152. 
Lean-seafood is rich in dietary protein; nonetheless, healthy dietary fats are also derived 
from seafood which may contribute to the changes in the lipid profiles. Desroches et al. 
previously reported that the intake of soy protein compared to animal protein resulted in 
an increase in the LDL-P size, decreased the content of LDL, and increased the 
cholesterol level in LDL123.  
In conclusion, the results indicate that both animal and plant protein consumption 
had beneficial effects on lipid profiles among men and women. However, it appears that 
males and females had different responses to animal and plant protein intake. Plant 
protein led to the greatest increase in HDL-cholesterol while animal protein had a more 
significant impact on LDL-cholesterol and total cholesterol reduction in men, whereas 
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plant protein was more beneficial for women. These results suggest that dietary 
interventions aimed at reducing the risk of CVD by producing favorable changes in the 
lipid profiles should contain adequate amounts of dietary protein.  
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